期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物制剂治疗系统性红斑狼疮新进展 被引量：1

下载PDF
导出
摘要 系统性红斑狼疮为免疫系统介导为主的疾病,糖皮质激素、免疫抑制剂是常用的治疗药物,虽然对部分患者治疗有效,但以上药物不良反应较多。部分生物制剂已运用于系统性红斑狼疮的临床治疗,主要对其展开综述。
作者 王蝶 吴金玉 黄娟
机构地区 广西中医药大学 广西中医药大学第一附属医院
出处 《风湿病与关节炎》 2016年第5期74-77,共4页 Rheumatism and Arthritis
关键词 红斑狼疮 系统性 生物制剂 综述
分类号 R593.241 [医药卫生—内科学]
  • 相关文献

参考文献15

  • 1Weidenbusch M,ROmmele C,Schrottle A,et al.Beyond the LUNAR trial.Efficacy of rituximab in refractory lupus nephritis [ J 1 .Nephrol Dial Transplant,2013,28 ( 1 ) :106-111.
  • 2王春燕,张娟,刘媛媛,王轶,王丽萍,张莉.小剂量利妥昔单抗治疗系统性红斑狼疮的临床观察[J].中华风湿病学杂志,2011,15(8):537-540. 被引量：12
  • 3Halim AG,Soehardy Z,Shahrir MS,et al.Rituximab in recalcitrant thrombotic thrombocytopenic purpura second- ary to systemic lupus erythematosus I J ~ .International Journal of Rheumatic Diseases,2008,11 ( 1 ) :69-72.
  • 4Daridon C,Blassfeld D,Reiter K,et al.Epratuzumab tar- geting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythemato-sus [ J ] .Arthritis Res Ther,2010,12 ( 6 ) :R204.
  • 5Cogollo E,Silva MA,Isenherg D.Profile of atacicept and its potential in the treatment of systemic lupus erythe- matosus[ J ].Drug Des Devel Ther,2015( 9 ):1331-1339.
  • 6Richard F,Michelle P,Omid Z,et al.A phase IlI,random- ized,placebo-controlled study of belimumab,a mono- clonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus [ J ] .Ar- thritis Rheum,2011,63 (12):3918-3930.
  • 7Strand V,Levy RA,Cervera R,et al.Improvements in health-related quality of life with belimumab,a B-lym- phocyte stimulator-specific inhibitor,in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials [ J ] .Ann Rheum Dis,2014,73 ( 5 ) :838-844.
  • 8周立偲,田浤,高向东,何书英.生物技术药物治疗系统性红斑狼疮的研究进展[J].药学与临床研究,2014,22(3):251-256. 被引量：11
  • 9Isenberg D,Gordon C,Licu D,et al.Efficacy and safety of atacicept for prevention of flares in patients with mod- erate-to-severe systemic lupus erythematosus ( SLE ) : 52-week data (APRIL-SLE randomised trial ) [ J ] . Ann Rheum Dis,2014,74 ( 11 ) :2006-2015.
  • 10Matsumura R,Umemiya K,Sugiyama T.Anti-tumor necrosis factor therapy in patients with diffficult-to-treat lupus nephritis:a prospective series of nine patients [ J ]. Clin Exp Rheumatol,2009,27 ( 3 ) :416-421.

二级参考文献41

  • 1Gunnarsson IVA, Sundelin B, Jonsdottir T, et al. Histopatholo- gic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum, 2007, 56: 1263-1272.
  • 2Tokunaga M, Saito K, Kawabata D,I et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus invol- ving the central nervous system. Ann Rheum Dis, 2007, 66: 470-475.
  • 3Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, openlabel pilot trial. Am J Respir Cfit Care Med, 2006, 173: 180-187.
  • 4Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum, 2005, 52: 601-607.
  • 5Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing- remitting multiple sclerosis. N Engl J Med, 2008, 358: 676-688.
  • 6Rodeghiere F, Stasi R, Gemsheimer T, et al. Standardization of technology,definitions and outcome criteria in immune thrombo- cytopenic purpura of adults and children: report from an intem- ational working group. Blood, 2009, 113 : 2386-2393.
  • 7Braendstrup P, Bjenum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult re- fractory idiopathic thrombocytopenie purpura. Am J Hematol,2005, 78: 275-280.
  • 8Arce-Salinas C, Rodriguez-Garcia F. Rituximab efficacy in the treatment of refractory lupus nephritis. Ann Rheum Dis, 2008, 67 Suppl 2: 211.
  • 9Smith KG, Jones RB, Bums SM, et al. Long - term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and retreatment. Arthritis Rheum, 2006, 54: 2970-2982.
  • 10Vigna-Perez M, Hemandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther, 2006, 8: R83.

共引文献22

同被引文献10

引证文献1

风湿病与关节炎
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部